Acasă › Boala Crohn › North Carolina
Studii clinice pentru Boala Crohn în North Carolina
20 studii pentru Boala Crohn caută participanți în North Carolina.
Orașe în North Carolina
Text oficial al studiului (în engleză)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 2 oct. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- și încă 1
În curs de recrutareFaza 4
Vârste de la 18 la 80 · Toate sexele · Actualizat 30 sept. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 25 sept. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- și încă 3
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
În curs de recrutareFaza 2
Vârste de la 18 la 85 · Toate sexele · Actualizat 22 sept. 2026 · NCT06226883A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
În curs de recrutareFaza 4
Vârste de 18 ani și peste · Femei · Actualizat 28 aug. 2026 · NCT07654751A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 aug. 2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 5 aug. 2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
În curs de recrutare
Vârste de la 18 la 44 · Femei · Actualizat 14 iul. 2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 24 iun. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
În curs de recrutareFaza 4
Vârste de la 6 la 17 · Toate sexele · Actualizat 27 mai 2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
În curs de recrutareStudiu observațional
Vârste de la 1 la 18 · Toate sexele · Actualizat 17 apr. 2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 27 mar. 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
În curs de recrutareFaza 2
Vârste de la 18 la 80 · Toate sexele · Actualizat 12 mar. 2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
În curs de recrutareStudiu observațional
Toate vârstele · Femei · Actualizat 17 iul. 2025 · NCT04846959Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.